IDIBELL on the media
New collaboration agreement with the ICR and Vivan Therapeutics to design new personalized treatments against cancer
A collaboration has been signed between the Bellvitge Biomedical Research Institute (IDIBELL), the Institute of Cancer Research (ICR) in London, and Vivan Therapeutics to jointly develop molecules that recognize more than one target for personalized treatment of colorectal cancer.
Barcelona becomes the European scientific capital of ALS thanks to the ENCALS International Congress
The local person in charge of the congress is Dra. Mònica Povedano, coordinator of the Motor Neuron Disease Functional Unit of the Bellvitge University Hospital (HUB) and principal researcher of the research group on Neurological and Neurogenetic Diseases of IDIBELL.
Monotherapy could replace combination therapy in endocarditis
Researchers from the Respiratory Infections and Immunocompromised Host group at IDIBELL and the Bellvitge University Hospital have shown that monotherapy with a 3rd generation cephalosporin is effective and safe as a treatment for this serious infectious disease. These results will change international recommendations for its management.
A heart stem cell-based model reveals why the same mutation affects two siblings with heart disease differently
Thanks to the model, the IDIBELL team detected that one of the siblings had an additional genetic variant responsible for the greater severity of the pathology. These models offer the possibility of exploring each patient’s pathology and designing an individualized approach.
The Clinical Research and Clinical Trials Unit obtains the ISO 9001:2015 recertification
Accreditation was first obtained in 2021 and requires an annual review to verify that the necessary requirements are maintained.
IDIBELL participates in a €10M European project to prevent childhood obesity
The European EprObes project, which uses a methodology based on Artificial Intelligence, will study how to prevent obesity through early identification of biomarkers, risk factors, prognosis and intervention.
3.2 million euros to identify new genetic variants responsible for hereditary cancers
The project, promoted by IDIBELL and CNIO, together with seven other research institutes, will combine artificial intelligence with cutting-edge molecular biology techniques to provide predictive medicine tools to the National Health Service.
A new treatment for lung cancer increases survival and could benefit more than 6,000 patients a year
The journal New England Journal of Medicine has published the results of the NADIM II study, which confirms the great benefit of chemo-immunotherapy with nivolumab before surgery on locally advanced tumors and is consolidated worldwide as the standard of treatment.
